Ask and ye shall receive: Biogen annual net income for the year ending... 2010-June-30: $1094M 2011-June-30: $1076M 2012-June-30: $1342M 2013-June-30: $1608

Ask and ye shall receive: Biogen annual net income for the year ending... 2010-June-30: $1094M 2011-June-30: $1076M 2012-June-30: $1342M 2013-June-30: $1608M 2014-June-30: $2140M 2015-June-30: $3490M Also, because someone asked, edgar has a bar chart breakdown of Biogen's product revenue. The lawsuit was about Biogen's drugs Avonex, Tysabri and Tecfidera. The bar chart (https://www.sec.gov/Archives/edgar/data/875045/000087504515000005/biib-2014pincipalproduct.jpg https://www.sec.gov/Archives/edgar/data/875045/0000875045150...) seems to indicate that these three were responsible for about 80-83% of Biogen's revenues (and presumably net income?) in 2014. I guess what we don't know is what their sales would have been like without the kickbacks? Less, presumably? But 0? Probably not.